Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Status:
Recruiting
Trial end date:
2027-04-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination
with enzalutamide compared with placebo in combination with enzalutamide in participants with
DDR-deficient mCSPC.